Feed BDX
BD

Becton, Dickinson and Company BDX NYSE · Healthcare · United States

$216.07 +0.30% +$0.65

Market cap
$58.9B
Enterprise value
$74.5B
P/E
51.4x
Forward P/E
15.6x
PEG
-
P/S
2.9x
P/FCF
21.3x
EV/EBITDA
15.7x
ROIC
4.1%
Gross margin
47.0%
Net margin
5.7%
Dividend yield
1.84%
Payout ratio
94.6%
Net debt/EBITDA
3.3x
Beta
0.28
Free float
99.8%

About the company

Becton, Dickinson and Company (BDX) is an American company operating in the field of healthcare technologies and medical devices. The company specializes in the development, manufacturing, and distribution of a wide range of products for diagnostics, therapy, and treatment in various healthcare areas. Its products include items such as needles, syringes, infectious disease diagnostic tests, diabetic products, and other medical devices. Becton, Dickinson and Company is known for its innovative technologies and high-quality products that contribute to improving patient care and enhancing the efficiency of medical procedures. The company operates globally and serves as a partner for healthcare institutions, hospitals, and medical professionals worldwide. Shares of Becton, Dickinson and Company (BDX) may represent an interesting investment opportunity for investors monitoring the healthcare sector and innovations in medical technologies.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Thomas E. Polen Jr.

Employees

60,000

Headquarters

Franklin Lakes

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What to watch: Earnings per share fell by 6.1% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 14 USD is left as free cash.
  • What to watch: It earns only 4.1 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

  • What speaks for it: It has raised its dividend 42 years in a row.
  • What speaks for it: It bought back its own shares for $2.43B in the last fiscal year, 4.1% of its market value.

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy